BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 31062389)

  • 1. Confirmation that somatic mutations of beta-2 microglobulin correlate with a lack of recurrence in a subset of stage II mismatch repair deficient colorectal cancers from the QUASAR trial.
    Barrow P; Richman SD; Wallace AJ; Handley K; Hutchins GGA; Kerr D; Magill L; Evans DG; Gray R; Quirke P; Hill J
    Histopathology; 2019 Aug; 75(2):236-246. PubMed ID: 31062389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatic mutations of the coding microsatellites within the beta-2-microglobulin gene in mismatch repair-deficient colorectal cancers and adenomas.
    Clendenning M; Huang A; Jayasekara H; Lorans M; Preston S; O'Callaghan N; Pope BJ; Macrae FA; Winship IM; Milne RL; Giles GG; English DR; Hopper JL; Win AK; Jenkins MA; Southey MC; Rosty C; Buchanan DD;
    Fam Cancer; 2018 Jan; 17(1):91-100. PubMed ID: 28616688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and Associations of Beta2-Microglobulin Mutations in MSI-H/dMMR Cancers.
    Liu F; Zhong F; Wu H; Che K; Shi J; Wu N; Fu Y; Wang Y; Hu J; Qian X; Fan X; Wang W; Wei J
    Oncologist; 2023 Mar; 28(3):e136-e144. PubMed ID: 36724040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor Budding
    Karlberg M; Stenstedt K; Hallström M; Ragnhammar P; Lenander C; Edler D
    Anticancer Res; 2018 Aug; 38(8):4713-4721. PubMed ID: 30061240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Difference analysis of somatic mutations between deficient mismatch repair and proficient mismatch repair gene related with colorectal cancer].
    Tang XJ; Yang MY; Zhu LZ; Xu D; Yuan Y
    Zhonghua Zhong Liu Za Zhi; 2021 Oct; 43(10):1088-1093. PubMed ID: 34695900
    [No Abstract]   [Full Text] [Related]  

  • 6. Prognostic impact of β-2-microglobulin expression in colorectal cancers stratified by mismatch repair status.
    Koelzer VH; Baker K; Kassahn D; Baumhoer D; Zlobec I
    J Clin Pathol; 2012 Nov; 65(11):996-1002. PubMed ID: 22859396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymphocytic response to tumour and deficient DNA mismatch repair identify subtypes of stage II/III colorectal cancer associated with patient outcomes.
    Williams DS; Mouradov D; Jorissen RN; Newman MR; Amini E; Nickless DK; Teague JA; Fang CG; Palmieri M; Parsons MJ; Sakthianandeswaren A; Li S; Ward RL; Hawkins NJ; Faragher I; Jones IT; Gibbs P; Sieber OM
    Gut; 2019 Mar; 68(3):465-474. PubMed ID: 29382774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinct Clinicopathological Patterns of Mismatch Repair Status in Colorectal Cancer Stratified by KRAS Mutations.
    Li W; Zhi W; Zou S; Qiu T; Ling Y; Shan L; Shi S; Ying J
    PLoS One; 2015; 10(6):e0128202. PubMed ID: 26042813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular patterns in deficient mismatch repair colorectal tumours: results from a French prospective multicentric biological and genetic study.
    Etienne-Grimaldi MC; Mahamat A; Chazal M; Laurent-Puig P; Olschwang S; Gaub MP; Formento JL; Formento P; Sudaka A; Boige V; Abderrahim-Ferkoune A; Benchimol D; André T; Houry S; Faucheron JL; Letoublon C; Gilly FN; Delpero JR; Lasser P; Pradere B; Pezet D; Penault-Llorca F; Milano G
    Br J Cancer; 2014 May; 110(11):2728-37. PubMed ID: 24800948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Next-generation sequencing reveals heterogeneous genetic alterations in key signaling pathways of mismatch repair deficient colorectal carcinomas.
    Wang J; Li R; He Y; Yi Y; Wu H; Liang Z
    Mod Pathol; 2020 Dec; 33(12):2591-2601. PubMed ID: 32620917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.
    Le Flahec G; Badic B; Guibourg B; Doucet L; Bail JP; Marcorelles P; Schick U; Uguen A
    Hum Pathol; 2018 Feb; 72():135-143. PubMed ID: 29208565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microsatellite instability in mismatch repair proficient colorectal cancer: clinical features and underlying molecular mechanisms.
    Xu Y; Liu K; Li C; Li M; Zhou X; Sun M; Zhang L; Wang S; Liu F; Xu Y
    EBioMedicine; 2024 May; 103():105142. PubMed ID: 38691939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topoisomerase-1 and -2A gene copy numbers are elevated in mismatch repair-proficient colorectal cancers.
    Sønderstrup IM; Nygård SB; Poulsen TS; Linnemann D; Stenvang J; Nielsen HJ; Bartek J; Brünner N; Nørgaard P; Riis L
    Mol Oncol; 2015 Jun; 9(6):1207-17. PubMed ID: 25777966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic and epigenetic analysis of the beta-2-microglobulin gene in microsatellite instable colorectal cancer.
    Snahnicanova Z; Kasubova I; Kalman M; Grendar M; Mikolajcik P; Gabonova E; Laca L; Caprnda M; Rodrigo L; Ciccocioppo R; Kruzliak P; Plank L; Lasabova Z
    Clin Exp Med; 2020 Feb; 20(1):87-95. PubMed ID: 31853669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response to Chemotherapy and Prognosis in Metastatic Colorectal Cancer With DNA Deficient Mismatch Repair.
    Alex AK; Siqueira S; Coudry R; Santos J; Alves M; Hoff PM; Riechelmann RP
    Clin Colorectal Cancer; 2017 Sep; 16(3):228-239. PubMed ID: 28063788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Targeted Next-Generation Sequencing Shows Increased Mutational Load in Endometrioid-type Endometrial Adenocarcinoma With Deficient DNA Mismatch Repair.
    Lee PJ; McNulty S; Duncavage EJ; Heusel JW; Hagemann IS
    Int J Gynecol Pathol; 2018 Nov; 37(6):581-589. PubMed ID: 29084048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B2M and JAK1/2-mutated MSI-H Colorectal Carcinomas Can Benefit From Anti-PD-1 Therapy.
    Zhang C; Li D; Xiao B; Zhou C; Jiang W; Tang J; Li Y; Zhang R; Han K; Hou Z; Zhang L; Sui Q; Liao L; Pan Z; Zhang X; Ding P
    J Immunother; 2022 May; 45(4):187-193. PubMed ID: 35343934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different surgical outcome and follow-up status between dMMR and pMMR colorectal cancer patients who fulfilled with Amsterdam-II criteria.
    Sun CY; Chiang JM; Chen TC; Hung HY; You JF
    World J Surg Oncol; 2020 Aug; 18(1):195. PubMed ID: 32767993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct microbes, metabolites, and ecologies define the microbiome in deficient and proficient mismatch repair colorectal cancers.
    Hale VL; Jeraldo P; Chen J; Mundy M; Yao J; Priya S; Keeney G; Lyke K; Ridlon J; White BA; French AJ; Thibodeau SN; Diener C; Resendis-Antonio O; Gransee J; Dutta T; Petterson XM; Sung J; Blekhman R; Boardman L; Larson D; Nelson H; Chia N
    Genome Med; 2018 Oct; 10(1):78. PubMed ID: 30376889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Characteristics and Outcomes of Treatment in Patients with Stage IV Colorectal Cancer with Mismatch Repair Deficiency].
    Ishibashi K; Chika N; Suzuki O; Ito T; Amano K; Kumamoto K; Fukuchi M; Kumagai Y; Mochiki E; Ishida H
    Gan To Kagaku Ryoho; 2016 Nov; 43(12):1711-1714. PubMed ID: 28133107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.